<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>jmedicalcasereports</PublisherName>
      <JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
      <PISSN>I</PISSN>
      <EISSN>S</EISSN>
      <Volume-Issue>Volume 3; Issue 5</Volume-Issue>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season>(Sep-Oct, 2022)</Season>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>-0001</Year>
        <Month>11</Month>
        <Day>30</Day>
      </PubDate>
      <ArticleType>Medical Case Reports</ArticleType>
      <ArticleTitle>A Lupus Flare Case, After Infection With COVID-19</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>1</FirstPage>
      <LastPage>6</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Artur</FirstName>
          <LastName>Zoto</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Melisa</FirstName>
          <LastName>Uruci</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Armida</FirstName>
          <LastName>Ajasllari</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Marsel</FirstName>
          <LastName>Broqi</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Nerenxa</FirstName>
          <LastName>Ajasllari</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI/>
      <Abstract>Introduction: Lupus is a systemic autoimmune disease with multi organ involvement, that develops a variety of clinical manifestations from dermatological ones to severe organ damage. Covid 19 is an infection with high mortality and morbidity, caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2 (CoV2). There are hypotheses on a burst of clinical manifestations of Systemic Lupus Erythematosus (SLE) after Covid 19, based on different literature reports. Here we present a clinical case of SLE with organ involvement, which aggravated after infection with SARS Cov2.&#13;
&#13;
Clinical case: A 30 year old young woman presented with aggravation of her musculoskeletal symptoms after infection with Covid 19. Before the coronavirus infection, she had joint pain, fatigue and subsequently developed systemic multiorgan involvement like lupus nephritis, pulmonary and hematological involvement. The patient gets diagnosed with SLE and begins treatment with Methylprednisolone 1 gram/day for three days, followed by ACE I (Ramipril 5 mg 1 tab/day), Mycophenolate 3 gram/day, Plaquenil 200 mg/day, Prednisone 1mg/kg body weight, Calcium, Vitamin D, PPI.&#13;
&#13;
Conclusion: With this clinical case we underline a hypothesis of a burst of clinical manifestations of autoimmune diseases, SLE in this case, probably because of a high titer of antibody production after infection with Covid 19.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>Systemic Lupus Erythematosus,SLEDAI,FLARE,Covid-19</Keywords>
      <URLs>
        <Abstract>https://jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=14071&amp;title=A Lupus Flare Case, After Infection With COVID-19</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References>Ahmed S, Zimba O, Gasparyan AY. COVID-19 and the clinical course of rheumatic manifestations. Clin Rheumatol 2021; 40: 2611-2619.&#13;
&#13;
Alharthy A, Faqihi F, Nasim N, Noor A, Akhtar S, Balshi A, Balhamar A, Alqahtani SA, Memish ZA, Karakitsos D. COVID-19 in a patient with a flare of systemic lupus erythematosus: A rare case-report. Respir Med Case Rep 2020; 31: 101252.&#13;
&#13;
Caso F, Costa L, Ruscitti P, Navarini L, Del Puente A, Giacomelli R, Scarpa R. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Autoimmun Rev 2020; 19: 102524.&#13;
&#13;
Caso F, Costa L, Ruscitti P, Navarini L, Del Puente A, Giacomelli R, Scarpa R. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Autoimmun Rev 2020; 19: 102524.&#13;
&#13;
Doaty S, Agrawal H, Bauer E, Furst DE. Infection and Lupus: Which Causes Which? Curr Rheumatol Rep 2016; 18: 13.&#13;
&#13;
Gazzaruso C, Carlo Stella N, Mariani G, Nai C, Coppola A, Naldani D, Gallotti P. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia. Clin Rheumatol 2020; 39: 2095-2097.&#13;
&#13;
Gracia-Ramos AE, Martin-Nares E, Hernand;aacute;ndez-Molina G. New Onset of Autoimmune Diseases Following COVID-19 Diagnosis. Cells 2021; 10: 3592.&#13;
&#13;
Gracia-Ramos AE, Saavedra-Salinas Mand;Aacute;. Can the SARS-CoV-2 infection trigger systemic lupus erythematosus? A case-based review. Rheumatol Int 2021; 41: 799-809.&#13;
&#13;
Illescas-Montes R, Corona-Castro CC, Melguizo-Rodrand;iacute;guez L, Ruiz C, Costela-Ruiz VJ. Infectious processes and systemic lupus erythematosus. Immunology 2019; 158: 153-160.&#13;
&#13;
James JA, Harley JB, Scofield RH. Role of viruses in systemic lupus erythematosus and Sjand;ouml;gren syndrome. Curr Opin Rheumatol 2001; 13: 370-376.&#13;
&#13;
James JA, Robertson JM. Lupus and Epstein-Barr. Curr Opin Rheumatol 2012; 24: 383-388.&#13;
&#13;
Khalid MZ, Rogers S, Fatima A, Dawe M, Singh R. A Flare of Systemic Lupus Erythematosus Disease After COVID-19 Infection: A Case of Lupus Cerebritis. Cureus 2021; 13: e16104.&#13;
&#13;
Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol 2021; 33: 155-162.&#13;
&#13;
Nelson P, Rylance P, Roden D, Trela M, Tugnet N. Viruses as potential pathogenic agents in systemic lupus erythematosus. Lupus 2014; 23: 596-605.&#13;
&#13;
Pollard CA, Morran MP, Nestor-Kalinoski AL. The COVID-19 pandemic: a global health crisis. Physiol Genomics 2020; 52: 549-557.&#13;
&#13;
Quaglia M, Merlotti G, De Andrea M, Borgogna C, Cantaluppi V. Viral Infections and Systemic Lupus Erythematosus: New Players in an Old Story. Viruses 2021; 13: 277.&#13;
&#13;
Raghavan S, Gonakoti S, Asemota IR, Mba B. A Case of Systemic Lupus Erythematosus Flare Triggered by Severe Coronavirus Disease 2019. J Clin Rheumatol 2020; 26: 234-235.&#13;
&#13;
Ramos-Casals M. Viruses and lupus: the viral hypothesis. Lupus 2008; 17: 163-165.&#13;
&#13;
Rigante D, Mazzoni MB, Esposito S. The cryptic interplay between systemic lupus erythematosus and infections. Autoimmun Rev 2014; 13: 96-102.&#13;
&#13;
Sacchi MC, Tamiazzo S, Stobbione P, Agatea L, De Gaspari P, Stecca A, Lauritano EC, Roveta A, Tozzoli R, Guaschino R, Bonometti R. SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci 2021; 14: 898-907.&#13;
&#13;
Spihlman AP, Gadi N, Wu SC, Moulton VR. COVID-19 and Systemic Lupus Erythematosus: Focus on Immune Response and Therapeutics. Front Immunol 2020; 11: 589474.&#13;
&#13;
Taeschler P, Cervia C, Zurbuchen Y, Hasler S, Pou C, Tan Z, Adamo S, Raeber ME, Band;auml;chli E, Rudiger A, Stand;uuml;ssi-Helbling M, Huber LC, Brodin P, Nilsson J, Probst-Mand;uuml;ller E, Boyman O. Autoantibodies in COVID-19 correlate with antiviral humoral responses and distinct immune signatures. Allergy 2022; 77: 2415-2430.&#13;
&#13;
Zamani B, Moeini Taba SM, Shayestehpour M. Systemic lupus erythematosus manifestation following COVID-19: a case report. J Med Case Rep 2021; 15: 29.</References>
      </References>
    </Journal>
  </Article>
</ArticleSet>